Halozyme Q4 revenue $230M (+27% YoY); reiterates 2024 guidance; $750M buyback

HALOZYME THERAPEUTICS, INC.

2023-FY EPS reported $2.10 revenue$829,253,000

Q4 revenue $230M (+27% YoY); GAAP EPS $0.65, non-GAAP EPS $0.82; FY23 revenue $829M (+26%).
2024 guidance: revenue $915-985M (10-19% growth), non-GAAP EPS $3.55-3.90 (28-41% growth).
New $750M share repurchase program announced, reflecting confidence in growth.
Partner milestones: argenx VYVGART Hytrulo FDA priority review for CIDP (PDUFA June 21); $23M milestone.
Roche's Tecentriq SC received EU approval; Takeda's HYQVIA approved for CIDP in US and EU.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HALOZYME THERAPEUTICS, INC. reported 2024 results: revenue $915-985 Million, EPS $3.55-3.90. Guidance reaffirmed.

Period: 2024
Revenue: $915-985 Million
EPS: $3.55-3.90
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

Reiterating 2024 Financial Guidance: Total Revenue of $915-985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $535-585 Million, Representing YOY Growth of 26- 37% and Non-GAAP Diluted EPS of $3.55-3.90, Representing YOY Growth of 28-41%

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HALOZYME THERAPEUTICS, INC. reported Full Year 2023 results: revenue $829.3 million, EPS $2.10.

Period: Full Year 2023
Revenue: $829.3 million
EPS: $2.10
Result: reported results

Exact text from the filing

Full Year 2023 Revenue Increased 26% YOY to $829 million; GAAP Diluted EPS of $2.10 and Non-GAAP Diluted EPS of $2.77

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HALOZYME THERAPEUTICS, INC. reported Fourth Quarter 2023 results: revenue $230.0 million, EPS $0.65.

Period: Fourth Quarter 2023
Revenue: $230.0 million
EPS: $0.65
Result: reported results

Exact text from the filing

Fourth Quarter Revenue Increased 27% YOY to $230 million; GAAP Diluted EPS of $0.65 and Non-GAAP Diluted EPS of $0.82

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

HALOZYME THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001159036-24-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.